Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 3
2005 4
2006 1
2007 1
2008 6
2009 2
2011 3
2012 4
2013 1
2014 4
2015 4
2016 4
2017 4
2018 3
2019 3
2020 4
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

48 results
Results by year
Filters applied: . Clear all
Page 1
Targeting DNA Damage Response in Prostate and Breast Cancer.
Wengner AM, Scholz A, Haendler B. Wengner AM, et al. Among authors: haendler b. Int J Mol Sci. 2020 Nov 4;21(21):8273. doi: 10.3390/ijms21218273. Int J Mol Sci. 2020. PMID: 33158305 Free PMC article. Review.
Transcriptional addiction in cancer cells is mediated by YAP/TAZ through BRD4.
Zanconato F, Battilana G, Forcato M, Filippi L, Azzolin L, Manfrin A, Quaranta E, Di Biagio D, Sigismondo G, Guzzardo V, Lejeune P, Haendler B, Krijgsveld J, Fassan M, Bicciato S, Cordenonsi M, Piccolo S. Zanconato F, et al. Among authors: haendler b. Nat Med. 2018 Oct;24(10):1599-1610. doi: 10.1038/s41591-018-0158-8. Epub 2018 Sep 17. Nat Med. 2018. PMID: 30224758 Free PMC article.
The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models.
Wengner AM, Siemeister G, Lücking U, Lefranc J, Wortmann L, Lienau P, Bader B, Bömer U, Moosmayer D, Eberspächer U, Golfier S, Schatz CA, Baumgart SJ, Haendler B, Lejeune P, Schlicker A, von Nussbaum F, Brands M, Ziegelbauer K, Mumberg D. Wengner AM, et al. Among authors: haendler b. Mol Cancer Ther. 2020 Jan;19(1):26-38. doi: 10.1158/1535-7163.MCT-19-0019. Epub 2019 Oct 3. Mol Cancer Ther. 2020. PMID: 31582533 Free article.
Dysregulated Transcriptional Control in Prostate Cancer.
Baumgart SJ, Nevedomskaya E, Haendler B. Baumgart SJ, et al. Among authors: haendler b. Int J Mol Sci. 2019 Jun 13;20(12):2883. doi: 10.3390/ijms20122883. Int J Mol Sci. 2019. PMID: 31200487 Free PMC article. Review.
Exploiting Epigenetic Alterations in Prostate Cancer.
Baumgart SJ, Haendler B. Baumgart SJ, et al. Among authors: haendler b. Int J Mol Sci. 2017 May 9;18(5):1017. doi: 10.3390/ijms18051017. Int J Mol Sci. 2017. PMID: 28486411 Free PMC article. Review.
Characterization of the Menin-MLL Interaction as Therapeutic Cancer Target.
Brzezinka K, Nevedomskaya E, Lesche R, Haegebarth A, Ter Laak A, Fernández-Montalván AE, Eberspaecher U, Werbeck ND, Moenning U, Siegel S, Haendler B, Eheim AL, Stresemann C. Brzezinka K, et al. Among authors: haendler b. Cancers (Basel). 2020 Jan 14;12(1):201. doi: 10.3390/cancers12010201. Cancers (Basel). 2020. PMID: 31947537 Free PMC article.
Targeting BET bromodomains for cancer treatment.
Jung M, Gelato KA, Fernández-Montalván A, Siegel S, Haendler B. Jung M, et al. Among authors: haendler b. Epigenomics. 2015;7(3):487-501. doi: 10.2217/epi.14.91. Epigenomics. 2015. PMID: 26077433 Review.
Bromodomains and their pharmacological inhibitors.
Gallenkamp D, Gelato KA, Haendler B, Weinmann H. Gallenkamp D, et al. Among authors: haendler b. ChemMedChem. 2014 Mar;9(3):438-64. doi: 10.1002/cmdc.201300434. Epub 2014 Feb 4. ChemMedChem. 2014. PMID: 24497428 Review.
48 results